drugset / Trial / NCT01810315

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

NCT01810315

Phase 1 Completed 40 enrolled CONRAD
Non-randomizedCrossoverOpen-label

Summary

Purpose of the study is to assess tenofovir (TFV) PK and PD endpoints, cervicovaginal safety parameters, susceptibility to HIV-1 infection, and objective measures of vaginal applicator use in premenopausal and postmenopausal women.

Timeline

Start
2013-09
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 4.4 g Other
Background Estradiol Other / unclassified 1 g Other

Indications

No indication recorded.